. La-survenue-dnelly-dequatre-ponchelle, une hémorragie cérébrale sous anticoagulant impose l'arrêt de celui-ci ainsi qu'une réversion. Il semble que la reprise précoce de l'héparine soit nécessaire pour les patients ayant une indication formelle d, AVK. ( Decavel P, 2010.

. Du-1er-janvier, 577 patients ont été hospitalisés en neurologie pour un AVC ischémique et 111, 2013.

. Vandermeerj, montraient que les femmes présentaient un risque supérieur d'évènements hémorragiques mineurs lors de la prise d'AVK (van der Meer FJ, Rosendaal FR, et al , 1993), mais la plupart des autres études ne retrouvent pas d'association entre le genre des patients et le risque de présenter un évènement hémorragique, 1993.

J. Ansell, J. Hirsh, and E. Hylek, Les interactions médicamenteuses font également partie des facteurs pouvant influencer un évènement hémorragique sous AVK. L'effet général de la plupart des interactions avec les anticoagulants est une élévation de l'INR, expliquant l'augmentation du risque hémorragique, 2012.

. Au-total, 895 cas d'effets hémorragiques ont été rapportés, dont 46% d'hémorragies majeures (416 cas). Cent trente trois effets hémorragiques touchent le site opératoire ou sa proximité, p.758

A. Hajje, A. Calop, N. Bosson, J. Calop, J. et al., Quels facteurs associ??s ?? la survenue d???un ??v??nement iatrog??ne h??morragique chez les patients sous antivitamines??K???, Annales Pharmaceutiques Fran??aises, vol.68, issue.1, pp.36-43, 2010.
DOI : 10.1016/j.pharma.2009.11.003

A. Alvarez-requejo and C. A. , Under-reporting of adverse drug reactions, European Journal of Clinical Pharmacology, vol.54, issue.6, pp.483-491, 1998.
DOI : 10.1007/s002280050498

C. Ansm-en-collaboration-avec, Etude des risques hémorragiques et thromboemboliques artériels liés au changement de traitement d'un médicament antivitamine K (AVK) vers un anticoagulant oral direct (AOD) chez les individus nécessitant une anticoagulation à long-terme en conditions réelles d'utilisation, 2014.

M. Ariesen, M. Tangelder, J. Lawson, B. Eikelboom, D. Grobbee et al., Risk of Major Haemorrhage in Patients after Infrainguinal Venous Bypass Surgery: Therapeutic Consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study, European Journal of Vascular and Endovascular Surgery, vol.30, issue.2, pp.154-163, 2005.
DOI : 10.1016/j.ejvs.2005.03.005

J. Arnsten, J. Gelfand, and D. Singer, Determinants of Compliance with Anticoagulation: A Case-Control Study, The American Journal of Medicine, vol.103, issue.1, pp.11-18, 1997.
DOI : 10.1016/S0002-9343(97)90048-6

L. Azoulay, V. Schneider-lindner, S. Filion, K. Suissa, and S. , Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study, Pharmacoepidemiology and Drug Safety, vol.18, issue.10, pp.343-50, 2010.
DOI : 10.1002/pds.1883

B. Bégaud, L'apport de la pharmaco-épidémiologie. Actualité et dossier en santé publique, pp.33-40, 1999.

B. Bégaud and M. K. , Rates of Spontaneous Reporting of Adverse Drug Reactions in France, JAMA: The Journal of the American Medical Association, vol.288, issue.13, p.1588, 2002.
DOI : 10.1001/jama.288.13.1588

A. Bensadon and M. E. , Rapport n RM2011-001P.). (Membres de l'Inspection Générale des Affaires Sociales) Enquête sur le Mediator(R) (synthèse), 2011.

R. Beyth, L. Quinn, and C. Landefeld, Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin ??????Access the ???Journal Club??? discussion of this paper at http://www.elsevier.com/locate/ajmselect/, The American Journal of Medicine, vol.105, issue.2, pp.91-100, 1998.
DOI : 10.1016/S0002-9343(98)00198-3

C. Biriell and E. I. , Reasons for Reporting Adverse Drug Reactions???Some Thoughts Based on an International Review, Pharmacoepidemiology and Drug Safety, vol.6, issue.1, pp.21-27, 1997.
DOI : 10.1002/(SICI)1099-1557(199701)6:1<21::AID-PDS259>3.0.CO;2-I

G. Bouvenot, B. J. , and -. , Rapport sur les anticoagulants oraux directs (AOD), 2014.

E. Chiquette, M. Amato, and H. Bussey, Comparison of an Anticoagulation Clinic With Usual Medical Care, Archives of Internal Medicine, vol.158, issue.15, pp.1641-1648, 1998.
DOI : 10.1001/archinte.158.15.1641

M. Chisholm, Enhancing transplant patients' adherence to medication therapy, Clinical Transplantation, vol.28, issue.1, pp.30-38, 2002.
DOI : 10.1001/archinte.160.14.2101

S. Chu and B. M. , https://www.cadth.ca/fr/le-traitement-par-antidotes-pour-neutraliserleffet-des-anticoagulants-oraux-directs . Consulté le 09 09, 2015, sur L'Agence canadienne des médicaments et des technologies de la santé, 2015.

C. Gozalo and B. T. , Surdosages asymptomatiques en antivitamines K. Sang Thrombose Vaisseaux, pp.56-68, 2008.

M. Coeuret-pellicer and M. Zins, Les bases de données de l'assurance maladie, 2006.

H. Collège-de-la, Accident vasculaire cérébral : prise en charge précoce (alerte, phase préhospitalière, phase hospitalière initiale, indications de la thrombolyse) Consulté le 10 18, 2014, sur has-sante, 2009.

L. Cornelissen and V. P. , Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction, Pharmacoepidemiology and Drug Safety, vol.48, issue.1, pp.76-81, 2008.
DOI : 10.1002/pds.1516

J. Dangoumau, J. Evreux, and J. Jouglard, Mehtod for determination of undesirable effects of drugs, Therapie, vol.33, issue.3, pp.373-381, 1978.

D. Roquefeuil, L. Studer, A. Neumann, A. Merlière, and Y. , septembre) L'échantillon généraliste de bénéficiaires : représentativité, portée et limites. Consulté le avril 2010, sur Points de repère- n°25, 2009.

. Hématomes-intracérébraux-spontanés, Emc neurologie, pp.17-046

I. Douglas and L. Smeeth, Exposure to antipsychotics and risk of stroke: self controlled case series study, BMJ, vol.337, issue.aug28 2, p.1227, 2008.
DOI : 10.1136/bmj.a1227

B. I. Eriksson and D. O. , Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-85, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

S. Fellows, J. Rosini, J. Curtis, and E. Volz, Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency, The Journal of Emergency Medicine, vol.44, issue.2, 2012.
DOI : 10.1016/j.jemermed.2012.02.042

S. Fihn, M. Mcdonell, D. Martin, J. Henikoff, D. Vermes et al., Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group, Ann Intern Med, issue.7, pp.118-511, 1993.

M. Gaglia and W. R. Jr, Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor, Circulation, vol.123, issue.4, pp.451-456, 2011.
DOI : 10.1161/CIRCULATIONAHA.110.985325

M. Gendron, Motivations et réticences des médecins généralistes à paticiper à un travail de pharmacovigilance : A propos d'un projet de réseau, 2013.

M. Gitter, T. Jaeger, T. Petterson, B. Gersh, and M. Silverstein, Bleeding and Thromboembolism During Anticoagulant Therapy:A Population-Based Study in Rochester, Minnesota, Mayo Clinic Proceedings, vol.70, issue.8, pp.725-758, 1995.
DOI : 10.4065/70.8.725

M. Goldberg, M. Zins, and F. Lert, Proposition pour la création d'un PLATE- FORME scientifique et technique pluri-organismes pour l'aide à la gestion de cohortes et de grandes enquêtes épidémiologiques, 2007.

M. Goldberg, Projet Plastico -Proposition pour la mise en place d'une plateforme scientifique et technique d'aide à la gestion de cohortes et de grandes enquêtes de santé publique. Récupéré sur http, 2010.

F. Haramburu and B. B. , Temporal trends in spontaneous reporting of unlabelled adverse drug reactions, British Journal of Clinical Pharmacology, vol.44, issue.3, pp.299-301, 1997.
DOI : 10.1046/j.1365-2125.1997.t01-1-00573.x

J. Harenberg and M. S. , New anticoagulants - promising and failed developments, British Journal of Pharmacology, vol.98, issue.2, 2012.
DOI : 10.1111/j.1476-5381.2011.01578.x

R. Hart and D. H. , Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial, Stroke, vol.43, issue.6, pp.1511-1517, 2012.
DOI : 10.1161/STROKEAHA.112.650614

L. Hazell and S. S. , Under-Reporting of Adverse Drug Reactions, Drug Safety, vol.29, issue.1, pp.385-96, 2006.
DOI : 10.2165/00002018-200629050-00003

A. Hello, L'hémostase et ses anomalies dans les maladies inflammatoires, 2008.

P. A. Hennerici, The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping), Cerebrovasc Dis, vol.36, pp.1-5, 2013.

J. Hixson-wallace, J. Dotson, and S. Blakey, Effect of Regimen Complexity on Patient Satisfaction and Compliance With Warfarin Therapy, Clinical and Applied Thrombosis/Hemostasis, vol.28, issue.1, pp.33-40, 2001.
DOI : 10.1177/107602960100700108

B. Hutten, A. Lensing, R. Kraaijenhagen, and M. Prins, Safety of Treatment with Oral Anticoagulants in the Elderly, Drugs & Aging, vol.14, issue.4, pp.303-315, 1999.
DOI : 10.2165/00002512-199914040-00005

E. Hylek and G. A. , Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med, vol.11349, issue.11, pp.1019-1026, 2003.

J. Imbs and W. M. , Comment prévoir et évaluer les effets indésirables des médicaments ?, 2007.

J. Imbs and W. M. , Pharmacovigilance, La Revue du Praticien, vol.52, pp.502-508, 2002.

R. Kazmi and L. B. , New anticoagulants: how to deal with treatment failure and bleeding complications, British Journal of Clinical Pharmacology, vol.62, issue.2, pp.593-603, 2011.
DOI : 10.1111/j.1365-2125.2011.04060.x

L. Kernan, S. Ito, F. Shirazi, and K. Boesen, Fatal gastrointestinal hemorrhage after a single dose of dabigatran, Clinical Toxicology, vol.93, issue.7, pp.571-574, 2012.
DOI : 10.1160/TH09-11-0758

P. Kuijer, B. Hutten, M. Prins, and H. Büller, Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous Thromboembolism, Archives of Internal Medicine, vol.159, issue.5, pp.457-60, 1999.
DOI : 10.1001/archinte.159.5.457

M. Kumle, Declining breast cancer incidence and decreased HRT use, The Lancet, vol.372, issue.9639, pp.608-618, 2008.
DOI : 10.1016/S0140-6736(08)61255-6

H. Labrosse, N. Vantard, K. Garcia, G. Leboucher, and B. Charpiat, Consultation de pharmacie et niveau de connaissance des patients hospitalis??s traits par des m??dicaments anti-vitamine K, Annales Pharmaceutiques Fran??aises, vol.64, issue.5, pp.344-353, 2006.
DOI : 10.1016/S0003-4509(06)75327-5

C. Lafuente-lafuente, E. Pautas, and J. Belmin, [Anticoagulation of older people: what is new ?, pp.187-196, 2013.

C. Landefeld and L. Goldman, Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy, The American Journal of Medicine, vol.87, issue.2, pp.144-52, 1989.
DOI : 10.1016/S0002-9343(89)80689-8

L. Duff and F. , Le PMSI en pratique. Récupéré sur http, 2010.

C. Lee and A. J. , Direct thrombin inhibitors, British Journal of Clinical Pharmacology, vol.103, issue.1, pp.581-92, 2011.
DOI : 10.1111/j.1365-2125.2011.03916.x

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195735

Y. Lee and J. Schommer, Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions, Am J Health Syst Pharm, issue.13, pp.53-1580, 1996.

S. Léger, B. Allenet, O. Pichot, G. Figari, J. Calop et al., Impact d???un programme d?????ducation th??rapeutique sur les attitudes de pr??vention vis-??-vis du risque iatrog??ne : ??tude pilote contr??l??e visant les patients sous anticoagulants oraux pour maladie thromboembolique veineuse, Journal des Maladies Vasculaires, vol.29, issue.3, pp.152-160, 2004.
DOI : 10.1016/S0398-0499(04)96737-6

. Récupéré, K. Wolski, S. Nicholis, and S. Nissen, Consulté le 10 18, 2014, sur http://www.sante.gouv.fr/les-chiffres-cles-de-l-avc Pioglitazone and risk of cardiovascular events in patients with diabetes mellitus : a meta-analysis of randomized trials, AVC.html Lincoff AM, pp.1216-1224, 2007.

C. Lionis, S. H. , and -. , Setting priorities and identifying barriers for general practice research in Europe. Results from an EGPRW meeting, Family Practice, vol.21, issue.5, pp.587-93, 2004.
DOI : 10.1093/fampra/cmh518

S. Malhotra, R. Karan, P. Pandhi, and S. Jain, Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance, Postgraduate Medical Journal, vol.77, issue.913, pp.77-703, 2001.
DOI : 10.1136/pmj.77.913.703

R. Martin and K. K. , Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study, BMJ, vol.317, issue.7151, pp.119-139, 1998.
DOI : 10.1136/bmj.317.7151.119

J. Mega and S. T. , Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI, JAMA, vol.304, issue.16, 2010.
DOI : 10.1001/jama.2010.1543

N. Mercier, Cours d'hémostase. Consulté le 10 18, 2014, sur The medical team Work

F. Michelet, Utilisation de nouveaux outils en pharmacovigilance : à propos du retrait du MÉDIATOR® (BENFLUOREX) Rennes, 2010.

K. W. Muir, Comparison of Neurological Scales and Scoring Systems for Acute Stroke Prognosis, Stroke, vol.27, issue.10, pp.1817-1837, 1996.
DOI : 10.1161/01.STR.27.10.1817

M. Nahon, Score NIHSS simplifié (SFNV) Consulté le, 1018.

N. Dequatre-ponchelle, M. , H. Hénon, M. P. , M. Pasquini et al., Vitamin K Antagonists?Associated Cerebral Hemorrhages What Are Their Characteristics? Stroke, pp.350-355, 2013.

I. Ogilvie and W. S. , Ischaemic stroke and bleeding rates in ???real-world??? atrial fibrillation patients, Thrombosis and Haemostasis, vol.106, issue.1, pp.34-44, 2011.
DOI : 10.1160/TH10-10-0674

T. Oxley and D. R. , Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Front Neurol, p.8383, 2011.

G. Palareti, N. Leali, S. Coccheri, M. Poggi, C. Manotti et al., Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy, Lancet, issue.9025, pp.348-423, 1996.

V. Pengo, C. Legnani, F. Noventa, and G. Palareti, ISCOAT Study Group.(Italian Study on Complications of Oral Anticoagulant Therapy) Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study, Thromb Haemost, vol.85, issue.3, pp.418-440, 2001.

P. Petersen, G. Boysen, J. Godtfredsen, E. Andersen, and B. Andersen, PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study, The Lancet, vol.333, issue.8631, pp.1-175, 1989.
DOI : 10.1016/S0140-6736(89)91200-2

C. Pierfitte and H. B. , Enquête d'opinion sur la pharmacovigilance Européenne : le sentiment des médecins francais, Thérapie, vol.50, issue.2, pp.171-173, 1995.

P. Muriel, Décembre) Accompagnement et suivi du patient sous anticoagulants antivitamines K : Organisation d'un entretien pharmaceutique, 2014.

P. Pouyanne, F. Haramburu, J. Imbs, B. Bégaud, . The-french-pharmacovigilance et al., Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

R. Rahme and Z. S. , The role of antiplatelet therapy in aneurysm coiling, Neurological Research, vol.330, issue.14, p.2014, 2014.
DOI : 10.3174/ajnr.A0818

Z. Ramjaun, Use of the hospital medical information system database (PMSI) to identify adverse drug reactions in a pediatric university hospital" 1. 31es journées de pharmacovigilance, Fundamental Clin Pharmacol, pp.23-25, 2010.

M. Reynolds, K. Fahrbach, O. Hauch, G. Wygant, R. Estok et al., Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation, Chest, vol.126, issue.6, pp.126-1938, 2004.
DOI : 10.1378/chest.126.6.1938

A. Rudnicka, D. Ashby, P. Brennan, and M. T. , Thrombosis Prevention Trial, Archives of Internal Medicine, vol.163, issue.12, pp.1454-60, 2003.
DOI : 10.1001/archinte.163.12.1454

E. Saligari, L. Belle, C. Berry, M. Gonod, V. Poiré et al., Evaluation of an education program of patients undergoing oral anticoagulation treatment, Ann Cardiol Angeiol, issue.5, pp.52-297, 2003.

M. Samama and F. Depasse, Des anciens aux nouveaux anticoagulants : le rôle du biologiste, Annales de biologie clinique, vol.67, issue.5, pp.527-561, 2009.

F. Schiele, J. Van-ryn, K. Canada, C. Newsome, E. Sepulveda et al., A specific antidote for dabigatran: functional and structural characterization, Blood, vol.121, issue.18, 2013.
DOI : 10.1182/blood-2012-11-468207

S. Schulman, Treatment of venous thromboembolism with dabigatran, Current Opinion in Pulmonary Medicine, vol.18, issue.5, pp.410-415, 2012.
DOI : 10.1097/MCP.0b013e32835466eb

URL : https://hal.archives-ouvertes.fr/hal-01030866

. Scorenih, Consulté le 10 18, 2014, sur protocoles-urgences

M. Sevin, Prise en charge de l'infartus cérébral aigu, 2010.

V. Siguret and P. Gaussem, Les médicaments antiplaquettaires (antiagrégants plaquettaires), 2007.

V. Siguret, Vitamine K : metabolisme, éléments de physiopathologie, implication dans la variabilité inter-et intra-individuelle de la réponse au traitement par les antivitamines K, Hématologie, vol.12, issue.6, pp.389-99, 2006.

. Synthèse, guide parcours de soins fibrillation atriale. (2014, mars) Consulté le octobre 18, 2014.

E. Tang, C. Lai, K. Lee, R. Wong, G. Cheng et al., Relationship Between Patients??? Warfarin Knowledge and Anticoagulation Control, Annals of Pharmacotherapy, vol.133, issue.1, pp.34-43, 2003.
DOI : 10.1345/aph.1A198

I. Tzoulaki, M. Molokhia, V. Curcin, M. Little, C. Millett et al., Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database, BMJ, vol.339, issue.dec03 1, p.4731, 2009.
DOI : 10.1136/bmj.b4731

F. Van-der-meer, F. Rosendaal, J. Vandenbroucke, and E. Briët, Bleeding complications in oral anticoagulant therapy. An analysis of risk factors, Archives of Internal Medicine, vol.153, issue.13, pp.1557-62, 1993.
DOI : 10.1001/archinte.153.13.1557

T. Vogel, B. Geny, G. Kaltenbach, and E. Andrès, Anticoagulation de la fibrillation atriale par les nouveaux anticoagulants chez la personne âgée : les limites de « l'Evidence-Based Medicine, Médecine thérapeutique, 2014.

M. Welsch and A. M. , Le réseau de pharmacovigilance francais : structures et missions, Presse Med, vol.2229, issue.2, pp.102-108, 2000.

R. White, R. Beyth, H. Zhou, and P. Romano, Major bleeding after hospitalization for deep-venous thrombosis, The American Journal of Medicine, vol.107, issue.5, pp.414-438, 1999.
DOI : 10.1016/S0002-9343(99)00267-3

C. Yeh and F. J. , Oral Direct Factor Xa Inhibitors, Circulation Research, vol.111, issue.8, pp.1069-78, 2012.
DOI : 10.1161/CIRCRESAHA.112.276741